샘플 요청 목록

 카트 문의
시장보고서
상품코드
1731905

세계의 1형 당뇨병 시장

Type 1 Diabetes
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 476 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 1형 당뇨병 시장은 2030년까지 212억 달러에 달할 전망

2024년에 155억 달러로 추정되는 세계의 1형 당뇨병 시장은 분석 기간인 2024-2030년에 CAGR 5.4%로 성장하며, 2030년에는 212억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 인슐린 펜은 CAGR 6.1%를 기록하며, 분석 기간 종료까지 94억 달러에 달할 것으로 예상됩니다. 인슐린 시린지 부문의 성장률은 분석 기간에 CAGR 6.1%로 추정됩니다.

미국 시장은 42억 달러, 중국은 CAGR 8.6%로 성장할 것으로 예측

미국의 1형 당뇨병 시장은 2024년에 42억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 43억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 8.6%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.6%와 5.4%로 예측됩니다. 유럽에서는 독일이 CAGR 3.5%로 성장할 것으로 예측됩니다.

세계의 1형 당뇨병 시장 - 주요 동향과 촉진요인 정리

왜 1형 당뇨병 관리가 복잡해지고 전문화되는가?

1형 당뇨병(T1D)은 췌장의 인슐린을 생산하는 베타세포의 파괴를 특징으로 하는 자가면역질환으로, 평생 인슐린 치료와 지속적인 대사 모니터링을 필요로 하는 질환으로, 2형 당뇨병과 달리 1형 당뇨병은 일반적으로 소아, 청소년, 청년 및 젊은 성인에게 발병하지만, 노인에게도 발병하는 경우가 많습니다. T1D 관리의 복잡성은 환자가 지속적으로 혈당을 모니터링하고, 탄수화물 섭취량을 계산하고, 인슐린을 정확하게 투여하고, 생활습관 및 생리적 변화에 대응해야 하는 일상적인 요구사항에 있습니다. 치료법의 발전에도 불구하고 저혈당, 케톤산증, 신증 및 망막증과 같은 장기적인 합병증과 같은 위험은 여전히 남아 있습니다. 최근 맞춤 치료 계획과 기술적으로 통합된 관리 시스템으로의 전환은 T1D에 대한 접근 방식을 변화시켰지만, 비용 부담, 데이터 과잉, 최신 툴에 대한 접근성 격차 등 새로운 과제를 야기하고 있습니다. 전 세계에서 T1D에 대한 인식과 진단이 향상됨에 따라 정교하고 확장 가능하며 환자 친화적인 솔루션에 대한 필요성이 그 어느 때보다 높아지고 있습니다.

기술 혁신은 어떻게 치료 패러다임을 재구성하고 있는가?

급속한 기술 발전은 환자에게 더 많은 자율성과 통제력을 제공함으로써 1형 당뇨병의 상황을 변화시키고 있습니다. 연속 혈당 모니터링(CGM) 시스템과 인슐린 펌프는 많은 환자들의 혈당 조절과 삶의 질을 획기적으로 향상시켰으며, CGM과 스마트폰, 스마트워치, 클라우드 플랫폼의 통합으로 실시간 모니터링, 동향 분석, 간병인의 원격 개입이 가능해졌습니다. 모니터링, 동향 분석, 간병인의 원격 개입이 가능해졌습니다. 하이브리드 폐쇄 루프 시스템(종종 인공 췌장 기술이라고도 함)은 실시간 포도당 데이터를 기반으로 인슐린 투여를 자동화하여 당뇨병 관리의 자동화를 향한 큰 도약을 나타냅니다. 또한 용량 추적 기능이 있는 스마트 펜, 디지털 건강 코칭 플랫폼, AI 기반 인슐린 용량 계산기는 사용자에게 실용적인 인사이트를 제공합니다. 이러한 툴은 치료 순응도를 높일 뿐만 아니라 합병증을 줄이는 데도 도움이 됩니다. 하지만, 특히 중저소득 국가에서는 여전히 가격, 상환, 기기 간 상호운용성 등이 장애물이 되고 있습니다. 그럼에도 불구하고 디지털 건강이 만성질환 관리의 중심축으로 자리 잡으면서 T1D 환자들은 지속적인 기술 혁신의 혜택을 누릴 수 있을 것입니다.

연구, 정책, 사회경제적 요인이 치료 접근성에 어떤 역할을 하는가?

획기적인 발전에도 불구하고 적절한 T1D 치료에 대한 접근성은 지역과 사회경제적 계층에 따라 큰 차이가 있습니다. 고소득 국가에서는 인슐린 치료, 첨단 의료기기, 체계적인 교육 프로그램 등에 대한 보조금을 받을 수 있습니다. 반면, 많은 중저소득 지역에서는 인슐린 부족, 진단 툴 부족, 당뇨병 교육을 위한 최소한의 의료 인프라에 직면해 있습니다. 특히 미국에서는 '인슐린 저가화 위기'가 전 세계의 주목을 받고 있으며, 정책 입안자들은 가격 규제, 투명성 제고, 바이오시밀러 개발 장려를 촉구하고 있으며, WHO와 IDF와 같은 국제기구는 인슐린을 필수의약품 리스트에 포함시킬 것을 주장하고 있으며, Life for a Child와 같은 구상은 인슐린과 진단 툴에 대한 무료 접근성을 제공하는 것을 목표로 하고 있습니다. 사회적 요인도 한몫을 하고 있습니다. 편견, 낮은 건강 문해력, 문화적 신화가 진단과 치료 순응도를 방해하는 경우가 많습니다. 따라서 전 세계의 노력은 치료법 혁신뿐만 아니라 공평한 분배, 교육, 제도적 의료 개혁에 초점을 맞추어야 합니다.

세계 1형 당뇨병 시장 확대의 원동력은?

1형 당뇨병 시장 성장의 원동력은 전 세계 유병률 증가, 조기 진단, 첨단 인슐린 전달 및 포도당 모니터링 기술의 채택 확대, 연구개발에 대한 활발한 투자 등 여러 가지 요인에 기인합니다. 진단 툴의 접근성이 높아짐에 따라 조기 발견율이 향상되어 적시에 개입하고 질병을 더 잘 통제할 수 있게 되었습니다. 소비자 행동도 진화하고 있으며, 환자와 간병인은 실시간 데이터, 개인화된 치료 계획, 적극적인 질병 관리를 지원하는 커넥티드 헬스 생태계를 점점 더 많이 요구하고 있습니다. 원격의료 및 원격 환자 모니터링 플랫폼의 확대로 원격지에서도 내분비 전문의나 당뇨병 전문의에게 접근할 수 있는 기회가 확대되고 있습니다. 기술적 측면에서는 바이오시밀러 인슐린, 스마트 웨어러블, 모바일 앱, AI 기반 예측 분석 등 지속적인 기술 혁신으로 인해 시장이 혜택을 받고 있습니다. 이와 함께 제약회사와 의료기술 회사들이 협력하여 과거에는 미래형이라고 여겨졌던 폐쇄형 루프 시스템을 개발하고 있습니다. 이러한 발전은 전 세계적인 인식 개선 캠페인과 정책적 지원과 함께 T1D 시장을 환자 중심의 기술 지원 치료의 새로운 시대로 이끌고 있습니다.

부문

디바이스 유형(인슐린 펜, 인슐린 시린지, 인슐린 펌프, 인슐린 제트 주사기); 인슐린 유형(장시간 작용형 인슐린, 속효형 인슐린); 최종사용자(재택 의료 현장, 병원·진료소, 학술·연구기관, 기타 최종사용자); 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업의 예(주목 44사)

  • Abbott Laboratories
  • Adocia SA
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Beta Bionics Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • CRISPR Therapeutics AG
  • Dexcom Inc.
  • Eli Lilly and Company
  • Insulet Corporation
  • Johnson & Johnson
  • MannKind Corporation
  • Medtronic plc
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Tandem Diabetes Care, Inc.
  • Vertex Pharmaceuticals Incorporated

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역 및 관세 영향 분석 :

미국 <gt; 중국 <gt; 멕시코 <gt; 캐나다 <gt;EU <gt; 일본 <gt; 인도 <gt; 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량경제 상황에서 이 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.09

Global Type 1 Diabetes Market to Reach US$21.2 Billion by 2030

The global market for Type 1 Diabetes estimated at US$15.5 Billion in the year 2024, is expected to reach US$21.2 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Insulin Pen, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$9.4 Billion by the end of the analysis period. Growth in the Insulin Syringe segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.2 Billion While China is Forecast to Grow at 8.6% CAGR

The Type 1 Diabetes market in the U.S. is estimated at US$4.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Type 1 Diabetes Market - Key Trends & Drivers Summarized

Why Is Type 1 Diabetes Management Becoming Increasingly Complex and Specialized?

Type 1 diabetes (T1D), an autoimmune condition characterized by the destruction of insulin-producing beta cells in the pancreas, requires lifelong insulin therapy and continuous metabolic monitoring. Unlike Type 2 diabetes, Type 1 typically develops in children, adolescents, and young adults, although its onset in older individuals is becoming more common. The complexity of managing T1D lies in its daily demands - patients must consistently monitor blood glucose levels, calculate carbohydrate intake, administer insulin accurately, and respond to lifestyle or physiological changes. Despite advances in therapy, risks such as hypoglycemia, ketoacidosis, and long-term complications like nephropathy and retinopathy persist. In recent years, the shift toward individualized care plans and tech-integrated management systems has transformed the approach to T1D, but it has also introduced new challenges, including cost burden, data overload, and disparities in access to modern tools. As awareness and diagnosis improve globally, the need for sophisticated, scalable, and patient-friendly solutions has never been greater.

How Are Technological Innovations Reshaping the Treatment Paradigm?

Rapid technological advancements are revolutionizing the Type 1 diabetes landscape, offering patients more autonomy and control than ever before. Continuous glucose monitoring (CGM) systems and insulin pumps have replaced finger-stick tests and manual injections for many, drastically improving glycemic control and quality of life. The integration of CGMs with smartphones, smartwatches, and cloud platforms enables real-time monitoring, trend analysis, and remote caregiver intervention. Hybrid closed-loop systems - often referred to as artificial pancreas technology - are automating insulin delivery based on real-time glucose data, representing a major leap toward automated diabetes management. Additionally, smart pens with dose tracking, digital health coaching platforms, and AI-driven insulin dose calculators are empowering users with actionable insights. These tools not only enhance treatment adherence but also help mitigate complications. However, affordability, reimbursement, and interoperability across devices remain hurdles, especially in low- and middle-income countries. Nevertheless, as digital health becomes a core pillar in chronic disease management, T1D patients stand to benefit significantly from continued innovation.

What Role Do Research, Policy, and Socioeconomic Factors Play in Access to Care?

Despite breakthroughs, access to adequate T1D care remains highly uneven across geographies and socioeconomic strata. In high-income countries, patients often benefit from subsidized insulin therapies, advanced devices, and structured education programs. In contrast, many low- and middle-income regions face insulin shortages, lack of diagnostic tools, and minimal healthcare infrastructure for diabetes education. The “insulin affordability crisis” - especially in the U.S. - has garnered global attention, with policymakers under pressure to regulate pricing, boost transparency, and incentivize biosimilar development. International organizations like the WHO and IDF are advocating for insulin to be included in essential medicines lists, and initiatives like Life for a Child aim to provide free access to insulin and diagnostic tools in underserved regions. Societal factors also play a role: stigma, low health literacy, and cultural myths often hinder diagnosis and treatment adherence. As a result, global efforts must not only focus on therapeutic innovation but also on equitable distribution, education, and systemic healthcare reforms.

What’s Driving the Expansion of the Type 1 Diabetes Market Worldwide?

The growth in the Type 1 diabetes market is driven by several factors, including the rising global prevalence of the disease, early-onset diagnosis, increased adoption of advanced insulin delivery and glucose monitoring technologies, and strong investments in research and development. As diagnostic tools become more accessible, early detection rates are improving, enabling timely intervention and better disease control. Consumer behavior is also evolving - patients and caregivers are increasingly seeking real-time data, personalized treatment plans, and connected health ecosystems that support proactive disease management. The expansion of telehealth and remote patient monitoring platforms is widening access to endocrinologists and diabetes specialists, even in remote areas. From a technological standpoint, the market is benefiting from continuous innovation in biosimilar insulin, smart wearables, mobile apps, and AI-based predictive analytics. In parallel, pharmaceutical and medtech companies are collaborating to develop closed-loop systems, once considered futuristic but now becoming mainstream. These advances, combined with global awareness campaigns and supportive policy shifts, are propelling the T1D market into a new era of patient-centric, technology-enabled care.

SCOPE OF STUDY:

The report analyzes the Type 1 Diabetes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Device Type (Insulin Pen, Insulin Syringe, Insulin Pump, Insulin Jet Injectors); Insulin Type (Long-Acting Insulin, Rapid-Acting Insulin); End-User (Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, Other End-Users); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • Adocia SA
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Beta Bionics Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • CRISPR Therapeutics AG
  • Dexcom Inc.
  • Eli Lilly and Company
  • Insulet Corporation
  • Johnson & Johnson
  • MannKind Corporation
  • Medtronic plc
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Tandem Diabetes Care, Inc.
  • Vertex Pharmaceuticals Incorporated

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Type 1 Diabetes - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expansion of CGM and Insulin Pump Adoption Drives Market for Tech-Enabled T1D Management
    • Integration of Artificial Pancreas Systems Strengthens Business Case for Automated Therapies
    • Increase in Pediatric Diabetes Cases Spurs Demand for Wearable and Miniaturized Devices
    • Rise in Health-Tech Startups Generates Innovation in AI-Driven Glucose Management Solutions
    • Shifting Toward Personalized Medicine Expands Role of Data Analytics in Treatment Protocols
    • Remote Patient Monitoring and Telehealth Platforms Sustain Access to Specialist Care
    • Insurance Reimbursement Reforms Propel Uptake of Advanced Insulin Delivery Systems
    • Growing Awareness of Hypoglycemia Risks Drives Demand for Predictive Monitoring Tools
    • Rise in DIY Looping Communities Creates Regulatory and Safety Framework Challenges
    • Mobile App Integration in Diabetes Management Tools Drives Real-Time User Engagement
    • Growth of Value-Based Healthcare Models Strengthens Emphasis on Outcome-Driven Interventions
    • Consumer Demand for Discreet and Stylish Devices Expands Innovation in Wearables
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Type 1 Diabetes Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Type 1 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Type 1 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Type 1 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Insulin Pen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Insulin Pen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Insulin Pen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Insulin Syringe by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Insulin Syringe by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Insulin Syringe by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Insulin Pump by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Insulin Pump by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Insulin Pump by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Insulin Jet Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Insulin Jet Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Insulin Jet Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Long-Acting Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Long-Acting Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Long-Acting Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Rapid-Acting Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Rapid-Acting Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Rapid-Acting Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • JAPAN
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • CHINA
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • EUROPE
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Type 1 Diabetes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Type 1 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • FRANCE
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • GERMANY
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Type 1 Diabetes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Type 1 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • INDIA
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Type 1 Diabetes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Type 1 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Type 1 Diabetes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Type 1 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030
  • AFRICA
    • Type 1 Diabetes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Type 1 Diabetes by Device Type - Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Type 1 Diabetes by Device Type - Percentage Breakdown of Value Sales for Insulin Pen, Insulin Syringe, Insulin Pump and Insulin Jet Injectors for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Type 1 Diabetes by End-user - Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Type 1 Diabetes by End-user - Percentage Breakdown of Value Sales for Other End-Users, Homecare Settings, Hospitals & Clinics and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Type 1 Diabetes by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Type 1 Diabetes by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Type 1 Diabetes by Insulin Type - Long-Acting Insulin and Rapid-Acting Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Type 1 Diabetes by Insulin Type - Percentage Breakdown of Value Sales for Long-Acting Insulin and Rapid-Acting Insulin for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제